Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
Short-Acting B2 Agonists Market Poised To Hit $5.39 Billion By 2030 With A 4.2% CAGR
The short-acting b2 agonists market size has shown consistent growth over recent years. This market is forecasted to increase from $4.4 billion in 2025 to $4.58 billion in 2026, achieving a compound annual growth rate (CAGR) of 4.1%. Historically, this expansion has been driven by factors including high asthma prevalence, the requirement for emergency respiratory care, the demand for rapid-acting bronchodilators, established hospital treatment protocols, and the accessibility of generic medications.
The short-acting b2 agonists market size is anticipated to experience steady expansion in the upcoming years. It will grow to $5.39 billion in 2030 at a compound annual growth rate (CAGR) of 4.2%. This growth during the forecast period is driven by factors such as increasing air pollution, the escalating burden of urban respiratory diseases, a rise in home inhaler usage, more pediatric asthma cases, and the expansion of outpatient respiratory care. Key trends for the forecast period include their continued role as first-line rescue medication, the increasing prevalence of asthma and COPD, a preference for inhalation-based delivery, the growth of homecare respiratory treatment, and the expansion of generic SABA products.
Get A Free Sample Report With In-Depth Market Insights:
Short-Acting B2 Agonists Market Growth Drivers: What’s Behind The Acceleration?
The growing incidence of chronic obstructive pulmonary disease (COPD) is anticipated to drive the expansion of the short-acting B2 agonists market in the future. COPD is a chronic respiratory condition characterized by breathing difficulties and diminished airflow, primarily resulting from extended exposure to detrimental gases or cigarette smoke. The uptick in chronic obstructive pulmonary disease (COPD) cases stems from greater exposure to air pollution, given that persistent inhalation of contaminants such as particulate matter and toxic gases can damage lung tissue and hasten the disease’s progression. Short-acting ß2-agonists (SABAs) provide rapid relief for COPD symptoms such as breathlessness by relaxing muscles in the airways. These serve as emergency drugs during exacerbations but are not intended for ongoing management. For example, in December 2023, a study published in JAMA Network Open, a medical journal from the American Medical Association, indicated that the worldwide prevalence of chronic obstructive pulmonary disease (COPD) could reach almost 600 million cases by 2050, representing a 23% rise in its occurrence. Consequently, the expanding incidence of chronic obstructive pulmonary disease is set to enhance the expansion of the short-acting B2 agonists market.
Short-Acting B2 Agonists Market Segment Outlook: Which Categories Are Growing Fastest?
The short-acting b2 agonists market covered in this report is segmented –
1) By Type: Albuterol, Levalbuterol, Metaproterenol, Other Types
2) By Indication: Asthama, Chronic Obstructive Pulmonary Disease (COPD), Exercise-Induced Bronchospasm
3) By Administration Route: Inhalation, Oral, Injection
4) By End User: Hospitals, Clinics, Home Healthcare Settings
Subsegments:
1) By Albuterol: Inhalers, Nebulizers, Tablets, Syrups
2) By Levalbuterol: Inhalers, Nebulizers, Oral Solutions
3) By Metaproterenol: Inhalers, Syrups
4) By Other Types: Terbutaline, Pirbuterol, Salbutamol
Short-Acting B2 Agonists Market Trends: What’s Defining The Industry’s Next Phase?
Leading companies within the short-acting B2 agonists market are concentrating on the development of advanced technological products, such as pressurized metered-dose inhalers (pMDI), aimed at effectively managing acute symptoms. Pressurized metered-dose inhalers (pMDIs) are portable devices designed to deliver a precise dose of medicine to the lungs as an aerosol, propelled by a spray, and are commonly utilized for addressing respiratory conditions like asthma and COPD. An illustrative example occurred in January 2023 when AstraZeneca, a pharmaceutical and biotechnology company based in the UK, announced that Airsupra (albuterol/budesonide) had received approval from the US Food and Drug Administration (FDA). Airsupra represents a novel, first-in-class pressurized metered-dose inhaler (pMDI) that combines two active components in a fixed-dose formulation. It incorporates albuterol, a short-acting beta2-agonist (SABA), to facilitate rapid bronchodilation, alongside budesonide, an inhaled corticosteroid (ICS), which acts to diminish inflammation. This distinct combination is sanctioned for use in the US for the on-demand treatment and prevention of bronchoconstriction in adult asthma patients. Furthermore, it contributes to lessening the likelihood of exacerbations, thereby offering a holistic method for asthma care.
Short-Acting B2 Agonists Market Leading Companies And Competitive Benchmarking
Major companies operating in the short-acting b2 agonists market are AstraZeneca plc, Novartis AG, GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd., Apotex Inc., Perrigo Company plc, Aurobindo Pharma Ltd., Chiesi Farmaceutici S.p.A., Cipla Limited, Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals Inc., Lupin Limited, Orion Corporation, Beximco Pharmaceuticals Ltd., Micro Labs Limited, Neuland Laboratories Limited, Vectura Group plc, Nephron Pharmaceuticals Corporation, AdvaCare Pharma USA LLC, Midas Care Pharmaceuticals Pvt Ltd.
View The Full Short-Acting B2 Agonists Market Report:
Short-Acting B2 Agonists Market Regional Analysis And Leading Geography
North America was the largest region in the short-acting B2 agonists market in 2025. The regions covered in the short-acting b2 agonists market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
